相关临床试验
462
35 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1479
进行中（未招募）
15
3.3%
已完成
324
70.1%
Enrolling By Invitation
4
0.9%
尚未招募
16
3.5%
招募中
45
9.7%
终止
7
1.5%
Unknown
49
10.6%
撤回
2
0.4%
暂无批准数据
- A nationwide Danish study of 79,510 adults with newly diagnosed type 2 diabetes found that consistent medication adherence reduced major cardiovascular events over a decade of follow-up. - People with low adherence faced a 27% higher rate of cardiovascular events, while intermediate adherence carried a 7% higher rate compared with consistent users. - High adherence was associated with an average of 220 additional days free from cardiovascular events, with the strongest effect seen for ischemic heart disease (45% higher rate in low-adherence patients). - Researchers call for early, personalized support soon after diagnosis, noting that adherence is shaped by social factors such as living alone, lower income, and other chronic conditions.
- Swedish biotech Atrogi has dosed the first subjects in a Phase 1 trial evaluating ATR-258, an oral therapy that mimics exercise effects by driving fat loss, increasing muscle, and improving metabolism. - The 8-week study will examine biased β2-adrenergic receptor signaling in overweight male volunteers receiving daily oral ATR-258 dosing to measure muscle physiological effects. - ATR-258 represents a first-in-class GRK2-biased β2-agonist designed to unlock therapeutic potential while avoiding cardiovascular side effects typically associated with this drug class. - The trial builds on landmark Cell publication data from June 2025 and previous 69-subject Phase 1 results demonstrating safety and tolerability in healthy volunteers and type 2 diabetes patients.
- Evosep unveiled the Evosep Eno, a high-throughput separation platform that can analyze over 500 samples per day and identify close to 7,000 proteins with 40% improved performance. - The new platform enables analysis of more than 2,000 proteins per minute while maintaining industry-leading system-to-system and lab-to-lab reproducibility for multi-site studies. - Evosep strengthened its strategic partnership with SCIEX through a reseller agreement, allowing SCIEX to offer the Evosep Eno alongside their mass spectrometers to pharmaceutical customers. - The collaboration aims to provide end-to-end solutions for drug development pipelines, enabling pharmaceutical companies to analyze a wider range of drug modalities more efficiently.
• Ousia Pharma has secured significant seed financing from Omega Funds to advance its dual-incretin-NMDA receptor antagonist conjugate for obesity treatment through preclinical and early clinical development. • The company's innovative approach leverages incretin hormone analogues to deliver small-molecule neuroplasticity modulators directly to brain appetite control centers, potentially addressing limitations of current GLP-1 therapies. • Industry veterans from AstraZeneca, including Prof. Sir Mene Pangalos and Dr. Elisabeth Björk, will join Ousia's Board of Directors, bringing extensive experience in cardiometabolic drug development.
- Glofitamab combined with polatuzumab vedotin shows high response rates and durable remissions in heavily pretreated relapsed/refractory large B-cell lymphoma (LBCL). - The combination demonstrates benefits across histologies, including high-grade B-cell lymphomas and those who failed previous CAR T-cell therapy. - The overall response rate was 80.6%, with a complete response rate of 62.0%, and a median duration of complete response of 37.8 months. - Combining glofitamab with salvage chemoimmunotherapy is safe and effective for patients with R/R DLBCL who are eligible for autologous stem cell transplant (ASCT) or CAR T-cell therapy.
- A recent study reveals that daily intake of vitamin B3 significantly reduces lung inflammation in individuals with Chronic Obstructive Pulmonary Disease (COPD). - The research demonstrated a notable decrease in interleukin 8 (IL-8), a key marker of inflammation, by 53% after six weeks and 63% after 18 weeks. - Vitamin B3 treatment also increased levels of NAD, a chemical that declines with age and DNA damage, suggesting potential benefits against cellular aging. - Researchers plan further studies to validate these findings and explore the long-term efficacy of nicotinamide riboside as a COPD treatment.
- A novel drug candidate, NK2R, has demonstrated weight loss effects in preclinical studies by targeting appetite and increasing calorie burning. - Unlike semaglutide (Ozempic), NK2R appears to spare muscle mass during weight loss, potentially offering a significant advantage. - The drug acts on a different neural circuit than GLP-1 agonists, targeting the neurokinin 2 receptor to influence blood sugar, body weight, and cholesterol. - Human clinical trials are planned within the next two years to assess the safety and efficacy of NK2R in overweight individuals.
